Clinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology

Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Clinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology”. It gives a robust idea about the patient recruitment status by geography, by Sponsor Company and by year for all the major orphan diseases in CNS and oncology. The report also compares the clinical trials and patient recruitment in orphan diseases with other diseases in CNS and oncology. Furthermore, the report provides profiles of prevalence forecast data up to 2017 for all the major indications. The major indications covered in the report are Huntington’s disease, Amyotrophic Lateral Sclerosis (ALS), ovarian disease, pancreatic disease, Hodgkin’s lymphoma, multiple myeloma and Acute Myeloid Leukemia (AML). It is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts.

An orphan disease is not common and its occurrence is said to be rare. These diseases have a low rate of prevalence in the existing population and a physician rarely gets to see patients with these conditions. Most of the orphan diseases are often genetic and hence they persist throughout a person’s life. It is estimated that 80% of orphan diseases have genetic origins. The remaining occurs due to allergies, degenerative causes, proliferative causes and as a result of infection. The symptoms for these diseases are not immediate and it occurs late for most of the conditions. The definition of orphan diseases varies with geography and is primarily dependent upon the prevalence of a disease.

In the US, orphan diseases are those that affect fewer than 6.6 per 10,000 (Orphan drug Act 1983). The US National Organization for Rate Disorders (NORD) has more than 1,200 diseases in their list while National Institute of Health (NIH)’s office for rare diseases published a list of more than 6,000 disease disorders ranging from Aagenaes syndrome to Zuska’s Disease. In Europe, orphan diseases are those that have a prevalence of less than 5 per 10,000 of the population. According to European Organization for Rare Diseases (EURORDIS), there are about 6,000 to 8,000 orphan diseases that exist in Europe. In Japan, orphan diseases are those that have a prevalence of less then 4 per 10,000 (Orphan Drug Act 1993).

The regulatory bodies play a crucial role in defining the orphan diseases as well as providing incentives to manufacturers who are involved in development of orphan drugs. Before the approval of orphan drugs, every molecule is designated as an orphan drug and will enter clinical trials. It is approved as an orphan drug only after the molecule clears the various phases in a clinical trial.

Clinical trials are one of the most critical parts of the drug development process. The various aspects involved in clinical trials such as implementation of technology, efficient supply chain management, proper site selection, patient recruitment, database management and others are important. Clinical trial recruitment is a time consuming process therefore good strategies need to be followed by pharmaceutical companies for adequate patient recruitment.

Scope

- Insight on Clinical Trials conducted for major indications of cardiology such as Huntington’s disease, ALS, ovarian cancer, pancreatic cancer, Hodgkin’s lymphoma, multiple myeloma and AML from 2000 to 2010.
- The status of patient recruitment by geography, Sponsor Company, year and stage of development.
- The comparison of clinical trials and patient recruitment in orphan diseases with other diseases in CNS and oncology
- Analysis on the average number of patients recruited per trial for major indications per year.
- Analysis on the average number of patients recruited per trial for major indications by stage of development.
- The prevalence population in the US, Europe and Japan for all major indications from 2010-2017.

Reasons to buy

- Identify and understand the status of clinical trials conducted for major orphan diseases from 2000 to 2010.
- Build understanding of patient recruitment status by geography, sponsor company, year and stage of development.
- Identify the prevalence within a population for major indications till 2017.
- Identify the average number of patients recruited by stage of development and across years for all major indications and the comparison with other diseases.
- Identify the indication in which the maximum number of trials is conducted and maximum number of patients recruited.

1.1 List of Tables 5
1.2 List of Figures 9
2 Clinical Trials in Orphan Diseases: Introduction 13
2.1 Disease Overview 13
2.1.1 The US 13
2.1.2 Europe 13
2.1.3 Japan 13
2.2 GBI Research Report Guidance 13
3 Clinical Trials and Patient Recruitment for Orphan Diseases in Central Nervous System(CNS) 14
3.1 Huntington’s disease 14
3.1.1 Introduction 14
3.1.2 Number of Clinical Trials for Huntington’s disease 15
3.1.3 Prevalence Population for Huntington’s disease (2010-2017) 19
3.1.4 Patient Recruitment for Huntington’s Disease 22
3.1.5 Average Number of Patients Recruited Per Trial 26
3.2 Amyotrophic Lateral Sclerosis (ALS) 28
3.2.1 Introduction 28
3.2.2 Number of Clinical Trials for Amyotrophic Lateral Sclerosis 29
3.2.3 Prevalence Population for ALS (2010-2017) 33
3.2.4 Patient Recruitment for Amyotrophic Lateral Sclerosis 36
3.2.5 Average Number of Patients Recruited Per Trial 40
3.3 Comparison of Clinical Trials and Patient Recruitment of Orphan Diseases with Other CNS Diseases 42
3.3.1 Number of Clinical Trials 42
3.3.2 Number of Patients Recruited 43
3.3.3 Average Number of Patients Recruited per Phase 44
3.3.4 Average Number of Patients Recruited per Year 45
4 Clinical Trials and Patient Recruitment for Orphan Diseases in Oncology 46
4.1 Ovarian Cancer 46
4.1.1 Introduction 46
4.1.2 Number of Clinical Trials for Ovarian Cancer 47
4.1.3 Prevalence Population for Ovarian Cancer (2010-2017) 51
4.1.4 Patient Recruitment for Ovarian Cancer 54
4.1.5 Average Number of Patients Recruited Per Trial 58
4.2 Pancreatic Cancer 60
4.2.1 Introduction 60
4.2.2 Number of Clinical Trials for Pancreatic Cancer 61
4.2.3 Prevalence Population for Pancreatic Cancer (2010-2017) 65
4.2.4 Patient Recruitment for Pancreatic cancer 68
4.2.5 Average Number of Patients Recruited Per Trial 72
4.3 Multiple Myeloma 74
4.3.1 Introduction 74
4.3.2 Number of Clinical Trials for Multiple Myeloma 75
4.3.3 Prevalence Population for Multiple Myeloma (2010-2017) 79
4.3.4 Patient Recruitment for Multiple Myeloma 82
4.3.5 Average Number of Patients Recruited Per Trial 86
4.4 Hodgkin’s Lymphoma 88
4.4.1 Introduction 88
4.4.2 Number of Clinical Trials for Hodgkin’s Lymphoma 88
4.4.3 Prevalence Population for Hodgkin’s Lymphoma (2010-2017) 93
4.4.4 Patient Recruitment for Hodgkin’s Lymphoma 96
4.4.5 Average Number of Patients Recruited Per Trial 100
4.5 Acute Myelocytic Leukemia (AML) 102
4.5.1 Introduction 102
4.5.2 Number of Clinical Trials for Acute Myelocytic Leukemia 103
4.5.3 Prevalence Population for Acute Myelocytic Leukemia (2010-2017) 107
4.5.4 Patient Recruitment for Multiple Myeloma 110
4.5.5 Average Number of Patients Recruited Per Trial 114
4.6 Comparison of Clinical Trials and Patient Recruitment of Orphan Diseases with Other Oncology Diseases 116
4.6.1 Number of Clinical Trials 116
4.6.2 Number of Patients Recruited 117
4.6.3 Average Number of Patients Recruited per Phase 118
4.6.4 Average Number of Patients Recruited per Year 119
5 Clinical Trial Recruitment in Orphan Diseases-Appendix 120
5.1 Market Definitions 120
5.2 Abbreviations 120
5.3 Research Methodology 120
5.3.1 Coverage 120
5.3.2 Secondary Research 121
5.3.3 Primary Research 121
5.3.4 Expert Panel Validation 121
5.3.5 Section-wise methodology 121
5.4 Contact Us 123
5.5 Disclaimer 123
5.6 Sources 123

1.1 List of Tables

Table 1: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Clinical Trials by Phase, 2000–2010 15
Table 2: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Clinical Trials by Major Sponsors, 2000–2010 16
Table 3: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Clinical Trials by Geography, 2000–2010 17
Table 4: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Clinical Trials by Year, 2000–2010 18
Table 5: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, The US, Prevalence Population, 2010–2017 19
Table 6: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Europe, Prevalence Population, 2010–2017 20
Table 7: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Japan, Prevalence Population, 2010–2017 21
Table 8: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Patients Recruited by Phase, 2000–2010 22
Table 9: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Patients Recruited by Major Sponsors, 2000–2010 23
Table 10: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Patients Recruited by Geography, 2000–2010 24
Table 11: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Patients Recruited by Year, 2000–2010 25
Table 12: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total, Average Number of Patients Recruited per Trial by Stage of Development, 2000–2010 26
Table 13: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total, Average Number of Patients Recruited per Trial per Year, 2000–2010 27
Table 14: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Clinical Trials by Phase, 2000–2010 29
Table 15: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Clinical Trials by Sponsor, 2000–2010 30
Table 16: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Clinical Trials by Geography, 2000–2010 31
Table 17: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Clinical Trials by Year, 2000–2010 32
Table 18: Clinical Trial Recruitment in Orphan Diseases, ALS, The US, Prevalence Population, 2010–2017 33
Table 19: Clinical Trial Recruitment in Orphan Diseases, ALS, Europe, Prevalence Population, 2010–2017 34
Table 20: Clinical Trial Recruitment in Orphan Diseases, ALS, Japan, Prevalence Population, 2010–2017 35
Table 21: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Patients Recruited by Phase, 2000–2010 36
Table 22: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Patients Recruited by Major Sponsors, 2000–2010 37
Table 23: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Patients Recruited by Geography, 2000–2010 38
Table 24: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Patients Recruited by Year, 2000–2010 39
Table 25: Clinical Trial Recruitment in Orphan Diseases, ALS, Average Number of Patients Recruited per Trial by Stage of Development, 2000–2010 40
Table 26: Clinical Trial Recruitment in Orphan Diseases, ALS, Average Number of Patients Recruited per Trial per Year, 2000–2010 41
Table 27: Clinical Trial Recruitment in Orphan Diseases, Comparison of Clinical Trials in Orphan Diseases With Other Diseases in CNS, Global, 2000–2010 42
Table 28: Clinical Trial Recruitment in Orphan Diseases, Comparison of Patients Recruited in Orphan Diseases With Other Diseases in CNS, Global, 2000–2010 43
Table 29: Clinical Trial Recruitment in Orphan Diseases, Average Number of Patients Recruited per Phase in Orphan Diseases Compared to Other Diseases in CNS, Global, 2000–2010 44
Table 30: Clinical Trial Recruitment in Orphan Diseases, Average Number of Patients Recruited per Year in Orphan Diseases Compared to Other Diseases in CNS, Global, 2000–2010 45
Table 31: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Clinical Trials by Phase, 2000–2010 47
Table 32: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Clinical Trials by Major Sponsors, 2000–2010 48
Table 33: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Clinical Trials by Geography, 2000–2010 49
Table 34: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Clinical Trials by Year, 2000–2010 50
Table 35: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, The US, Prevalence Population, 2010–2017 51
Table 36: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Europe, Prevalence Population, 2010–2017 52
Table 37: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Japan, Prevalence Population, 2010–2017 53
Table 38: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Patients Recruited by Phase, 2000–2010 54
Table 39: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Patients Recruited by Major Sponsors, 2000–2010 55
Table 40: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Patients Recruited by Geography, 2000–2010 56
Table 41: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Patients Recruited per Year, 2000–2010 57
Table 42: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Average Number of Patients Recruited per Trial by Stage of Development, 2000–2010 58
Table 43: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Average Number of Patients Recruited per Trial per Year, 2000–2010 59
Table 44: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Clinical Trials by Phase, 2000–2010 61
Table 45: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Clinical Trials by Major Sponsors, 2000–2010 62
Table 46: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Clinical Trials by Geography, 2000–2010 63
Table 47: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Clinical Trials per Year, 2000–2010 64
Table 48: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, The US, Prevalence Population, 2010–2017 65
Table 49: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Europe, Prevalence Population, 2010–2017 66
Table 50: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Japan, Prevalence Population, 2010–2017 67
Table 51: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Patients Recruited by Phase, 2000–2010 68
Table 52: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Patients Recruited by Major Sponsors, 2000–2010 69
Table 53: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Patients Recruited by Geography, 2000–2010 70
Table 54: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Patients Recruited per Year, 2000–2010 71
Table 55: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Average Number of Patients Recruited per Trial by Stage of Development, 2000–2010 72
Table 56: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Average Number of Patients Recruited per Trial per Year, 2000–2010 73
Table 57: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Clinical Trials by Phase, 2000–2010 75
Table 58: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Clinical Trials by Major Sponsors, 2000–2010 76
Table 59: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Clinical Trials by Geography, 2000–2010 77
Table 60: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Clinical Trials per Year, 2000–2010 78
Table 61: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, The US, Prevalence Population, 2010–2017 79
Table 62: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Europe, Prevalence Population, 2010–2017 80
Table 63: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Japan, Prevalence Population, 2010–2017 81
Table 64: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Patients Recruited by Phase, 2000–2010 82
Table 65: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Patients Recruited by Major Sponsors, 2000–2010 83
Table 66: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Patients Recruited by Geography, 2000–2010 84
Table 67: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Patients Recruited per Year, 2000–2010 85
Table 68: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Average Number of Patients Recruited per Trial by Stage of Development, 2000–2010 86
Table 69: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Average Number of Patients Recruited per Trial per Year, 2000–2010 87
Table 70: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Clinical Trials by Phase, 2000–2010 89
Table 71: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Clinical Trials by Major Sponsors, 2000–2010 90
Table 72: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Clinical Trials by Geography, 2000–2010 91
Table 73: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Clinical Trials per Year, 2000–2010 92
Table 74: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, The US, Prevalence Population, 2010-2017 93
Table 75: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Europe, Prevalence Population, 2010-2017 94
Table 76: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Japan, Prevalence Population, 2010-2017 95
Table 77: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Patients Recruited by Phase, 2000–2010 96
Table 78: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Patients Recruited by Major Sponsors, 2000–2010 97
Table 79: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Patients Recruited by Geography, 2000–2010 98
Table 80: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Patients Recruited per Year, 2000–2010 99
Table 81: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Average Number of Patients Recruited per Trial by Stage of Development, 2000–2009 100
Table 82: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Average Number of Patients Recruited per Trial per Year, 2000–2010 101
Table 83: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Clinical Trials by Phase, 2000–2010 103
Table 84: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Clinical Trials by Major Sponsors, 2000–2010 104
Table 85: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Clinical Trials by Geography, 2000–2010 105
Table 86: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Clinical Trials per Year, 2000–2010 106
Table 87: Clinical Trial Recruitment in Orphan Diseases, AML, The US, Prevalence Population, 2010-2017 107
Table 88: Clinical Trial Recruitment in Orphan Diseases, AML, Europe, Prevalence Population, 2010-2017 108
Table 89: Clinical Trial Recruitment in Orphan Diseases, AML, Japan, Prevalence Population, 2010-2017 109
Table 90: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Patients Recruited by Phase, 2000–2010 110
Table 91: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Patients Recruited by Major Sponsors, 2000–2010 111
Table 92: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Patients Recruited by Geography, 2000–2010 112
Table 93: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Patients Recruited per Year, 2000–2010 113
Table 94: Clinical Trial Recruitment in Orphan Diseases, AML, Average Number of Patients Recruited per Trial by Stage of Development, 2000–2010 114
Table 95: Clinical Trial Recruitment in Orphan Diseases, AML, Average Number of Patients Recruited per Trial per Year, 2000–2010 115
Table 96: Clinical Trial Recruitment in Orphan Diseases, Clinical Trials in Orphan Diseases Compared To Other Diseases In Oncology, Global, 2000–2010 116
Table 97: Clinical Trial Recruitment in Orphan Diseases, Total Patients Recruited in Orphan Diseases Compared To Other Diseases In Oncology, Global, 2000–2010 117
Table 98: Clinical Trial Recruitment in Orphan Diseases, Average Number of Patients Recruited per Phase in Orphan Diseases Compared To Other Diseases In Oncology, Global, 2000–2010 118
Table 99: Clinical Trial Recruitment in Orphan Diseases, Average Number of Patients Recruited per Year in Orphan Diseases Compared To Other Diseases In Oncology, Global, 2000–2010 119

1.2 List of Figures

Figure 1: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Clinical Trials by Phase, 2000–2010 15
Figure 2: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Clinical Trials by Major Sponsors, 2000–2010 16
Figure 3: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Clinical Trials by Geography, 2000–2010 17
Figure 4: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Clinical Trials by Year, 2000–2010 18
Figure 5: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, The US, Prevalence Population, 2010–2017 19
Figure 6: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Europe, Prevalence Population, 2010–2017 20
Figure 7: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Japan, Prevalence Population, 2010–2017 21
Figure 8: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Patients Recruited by Phase, 2000–2010 22
Figure 9: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Patients Recruited by Major Sponsors, 2000–2010 23
Figure 10: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Patients Recruited by Geography, 2000–2010 24
Figure 11: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Patients Recruited by Year, 2000–2010 25
Figure 12: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total, Average Number of Patients Recruited per Trial by Stage of Development, 2000–2010 26
Figure 13: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total, Average Number of Patients Recruited per Trial per Year, 2000–2010 27
Figure 14: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Clinical Trials by Phase, 2000–2010 29
Figure 15: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Clinical Trials by Sponsor, 2000–2010 30
Figure 16: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Clinical Trials by Geography, 2000–2010 31
Figure 17: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Clinical Trials by Year, 2000–2010 32
Figure 18: Clinical Trial Recruitment in Orphan Diseases, ALS, The US, Prevalence Population, 2010–2017 33
Figure 19: Clinical Trial Recruitment in Orphan Diseases, ALS, Europe, Prevalence Population, 2010–2017 34
Figure 20: Clinical Trial Recruitment in Orphan Diseases, ALS, Japan, Prevalence Population, 2010–2017 35
Figure 21: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Patients Recruited by Phase, 2000–2010 36
Figure 22: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Patients Recruited by Major Sponsors, 2000–2010 37
Figure 23: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Patients Recruited by Geography, 2000–2010 38
Figure 24: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Patients Recruited by Year, 2000–2010 39
Figure 25: Clinical Trial Recruitment in Orphan Diseases, ALS, Average Number of Patients Recruited per Trial by Stage of Development, 2000–2010 40
Figure 26: Clinical Trial Recruitment in Orphan Diseases, ALS, Average Number of Patients Recruited per Trial per Year, 2000–2010 41
Figure 27: Clinical Trial Recruitment in Orphan Diseases, Comparison of Clinical Trials in Orphan Diseases With Other Diseases in CNS, Global, 2000–2010 42
Figure 28: Clinical Trial Recruitment in Orphan Diseases, Comparison of Patients Recruited in Orphan Diseases With Other Diseases in CNS, Global, 2000–2010 43
Figure 29: Clinical Trial Recruitment in Orphan Diseases, Average Number of Patients Recruited per Phase in Orphan Diseases Compared to Other Diseases in CNS, Global, 2000–2010 44
Figure 30: Clinical Trial Recruitment in Orphan Diseases, Average Number of Patients Recruited per Year in Orphan Diseases Compared to Other Diseases in CNS, Global, 2000–2010 45
Figure 31: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Patients Recruited by Phase, 2000–2010 47
Figure 32: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Clinical Trials by Major Sponsors, 2000–2010 48
Figure 33: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Clinical Trials by Geography, 2000–2010 49
Figure 34: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Clinical Trials by Year, 2000–2010 50
Figure 35: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, The US, Prevalence Population, 2010–2017 51
Figure 36: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Europe, Prevalence Population, 2010–2017 52
Figure 37: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Japan, Prevalence Population, 2010–2017 53
Figure 38: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Patients Recruited by Phase, 2000–2010 54
Figure 39: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Patients Recruited by Major Sponsors, 2000–2010 55
Figure 40: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Patients Recruited by Geography, 2000–2010 56
Figure 41: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Patients Recruited per Year, 2000–2010 57
Figure 42: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Average Number of Patients Recruited per Trial by Stage of Development, 2000–2010 58
Figure 43: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Average Number of Patients Recruited per Trial per Year, 2000–2010 59
Figure 44: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Clinical Trials by Phase, 2000–2010 61
Figure 45: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Clinical Trials by Major Sponsors, 2000–2010 62
Figure 46: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Clinical Trials by Geography, 2000–2010 63
Figure 47: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Clinical Trials per Year, 2000–2010 64
Figure 48: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, The US, Prevalence Population, 2010–2017 65
Figure 49: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Europe, Prevalence Population, 2010–2017 66
Figure 50: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Japan, Prevalence Population, 2010–2017 67
Figure 51: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Patients Recruited by Phase, 2000–2010 68
Figure 52: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Patients Recruited by Major Sponsors, 2000–2010 69
Figure 53: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Patients Recruited by Geography, 2000–2010 70
Figure 54: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Patients Recruited per Year, 2000–2010 71
Figure 55: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Average Number of Patients Recruited per Trial by Stage of Development, 2000–2010 72
Figure 56: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Average Number of Patients Recruited per Trial per Year, 2000–2010 73
Figure 57: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Clinical Trials by Phase, 2000–2010 75
Figure 58: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Clinical Trials by Major Sponsors, 2000–2010 76
Figure 59: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Clinical Trials by Geography, 2000–2010 77
Figure 60: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Clinical Trials per Year, 2000–2010 78
Figure 61: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, The US, Prevalence Population, 2010–2017 79
Figure 62: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Europe, Prevalence Population, 2010–2017 80
Figure 63: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Japan, Prevalence Population, 2010–2017 81
Figure 64: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Patients Recruited by Phase, 2000–2010 82
Figure 65: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Patients Recruited by Major Sponsors, 2000–2010 83
Figure 66: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Patients Recruited by Geography, 2000–2010 84
Figure 67: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Patients Recruited per Year, 2000–2010 85
Figure 68: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Average Number of Patients Recruited per Trial by Stage of Development, 2000–2010 86
Figure 69: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Average Number of Patients Recruited per Trial per Year, 2000–2010 87
Figure 70: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Clinical Trials by Phase, 2000–2010 88
Figure 71: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Clinical Trials by Major Sponsors, 2000–2010 90
Figure 72: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Clinical Trials by Geography, 2000–2010 91
Figure 73: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Clinical Trials per Year, 2000–2010 92
Figure 74: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, The US, Prevalence Population, 2010-2017 93
Figure 75: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Europe, Prevalence Population, 2010-2017 94
Figure 76: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Japan, Prevalence Population, 2010-2017 95
Figure 77: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Patients Recruited by Phase, 2000–2010 96
Figure 78: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Patients Recruited by Major Sponsors, 2000–2010 97
Figure 79: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Patients Recruited by Geography, 2000–2010 98
Figure 80: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Patients Recruited per Year, 2000–2010 99
Figure 81: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Average Number of Patients Recruited per Trial by Stage of Development, 2000–2009 100
Figure 82: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Average Number of Patients Recruited per Trial per Year, 2000–2010 101
Figure 83: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Clinical Trials by Phase, 2000–2010 103
Figure 84: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Clinical Trials by Major Sponsors, 2000–2010 104
Figure 85: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Clinical Trials by Geography, 2000–2010 105
Figure 86: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Clinical Trials per Year, 2000–2010 106
Figure 87: Clinical Trial Recruitment in Orphan Diseases, AML, The US, Prevalence Population, 2010-2017 107
Figure 88: Clinical Trial Recruitment in Orphan Diseases, AML, Europe, Prevalence Population, 2010-2017 108
Figure 89: Clinical Trial Recruitment in Orphan Diseases, AML, Japan, Prevalence Population, 2010-2017 109
Figure 90: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Patients Recruited by Phase, 2000–2010 110
Figure 91: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Patients Recruited by Major Sponsors, 2000–2010 111
Figure 92: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Patients Recruited by Geography, 2000–2010 112
Figure 93: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Patients Recruited per Year, 2000–2010 113
Figure 94: Clinical Trial Recruitment in Orphan Diseases, AML, Average Number of Patients Recruited per Trial by Stage of Development, 2000–2010 114
Figure 95: Clinical Trial Recruitment in Orphan Diseases, AML, Average Number of Patients Recruited per Trial per Year, 2000–2010 115
Figure 96: Clinical Trial Recruitment in Orphan Diseases, Clinical Trials in Orphan Diseases Compared To Other Diseases In Oncology, Global, 2000–2010 116
Figure 97: Clinical Trial Recruitment in Orphan Diseases, Total Patients Recruited in Orphan Diseases Compared To Other Diseases In Oncology, Global, 2000–2010 117
Figure 98:Clinical Trial Recruitment in Orphan Diseases, Average Number of Patients Recruited per Phase in Orphan Diseases Compared To Other Diseases In Oncology, Global, 2000–2010 118
Figure 99:Clinical Trial Recruitment in Orphan Diseases, Average Number of Patients Recruited per Year in Orphan Diseases Compared To Other Diseases In Oncology, Global, 2000–2010 119